Oxford Biomedica PLC

Regulatory Filings • Dec 21, 2022

National Storage Mechanism | Additional information

RNS Number : 4910K

Oxford Biomedica PLC

21 December 2022

Oxford Biomedica to Present at 41st Annual J.P Morgan Healthcare Conference

Oxford, UK - 21 December 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that Stuart Paynter, Chief Financial Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, 11 January 2023 at  4.30pm PT. The presentation will be available on the Oxford Biomedica website after the conference at www.oxb.com/investors/results-reports-presentations-webcasts.

-Ends-

Enquiries:       

Oxford Biomedica plc:

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 919 539 1234

Sophia Bolhassan, VP, Head of Corporate Affairs - T: +44 (0)7394 562 425

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Matthew Cole            / Angela Gray

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Further information is available at www.oxb.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUAVRRUWUUUAA